NAMI
VRDN icon

Nomura Asset Management International’s Viridian Therapeutics VRDN Stock Holding History

Nomura Asset Management International’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$540K Sell
29,370
-56,020
-66% -$903K ﹤0.01% 1260
2026
Q1 		$1.67M Sell
85,390
-69,349
-45% -$2.06M ﹤0.01% 1011
2025
Q4 		$4.82M Buy
+154,739
New +$4.24M 0.01% 810

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nomura Asset Management International's VRDN Position: Q2 2026 in Review

Nomura Asset Management International reduced its Viridian Therapeutics (VRDN) stake by 66% in Q2 2026, selling an estimated $903K and leaving 29,370 shares worth $540K. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Nomura Asset Management International first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.82M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Nomura Asset Management International held 29,370 shares of Viridian Therapeutics worth $540K as of Q2 2026.
  • Nomura Asset Management International sold 56,020 Viridian Therapeutics shares in Q2 2026, an estimated $903K.
  • Viridian Therapeutics made up ﹤0.01% of Nomura Asset Management International's portfolio in Q2 2026, its #1260 holding.
  • Nomura Asset Management International first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Nomura Asset Management International's Viridian Therapeutics position peaked at $4.82M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Nomura Asset Management International's 13F filing for Q2 2026, filed 14 Aug 2026.